• Title/Summary/Keyword: Vaccines

Search Result 765, Processing Time 0.028 seconds

Current Status and Future Directions of Fish Vaccines in Korea (국내 수산용 백신 개발 현황 및 발전 방향)

  • Han, Hyun-Ja;Kim, Soo-Jin;Kim, Tae-Ho;Kim, Myoung-Sug;Cho, Mi-Young;Choi, Hye Sung
    • Korean Journal of Fisheries and Aquatic Sciences
    • /
    • v.54 no.4
    • /
    • pp.369-376
    • /
    • 2021
  • In Korea, fish is a major food source, and sustainable production of fish is critical for the aquaculture industry. Recently, infectious diseases have become an unavoidable problem in aquaculture and have caused serious economic losses. Therefore, there is an urgent need to overcome this challenge to increase productivity in aquaculture. Vaccination is the most effective and long-term measure for improving the management of a fish farm. Sales of fish vaccines in Korea have been steadily increasing, with a confirmed increase from 600 million won in 2007 to 3.4 billion won in 2018. As of 2021, 30 licensed fish vaccines, including both single and combination vaccines containing more than two inactivated pathogens, have been approved in Korea for 10 fish pathogens. Twenty-eight of these are used in olive flounder Paralichthys olivaceus; however, only two vaccines are used in starry flounder Platichthys stellatus, red seabream Ragrus major and rock bream Oplegnathus fasciatus. Therefore, vaccine development is required not only for the olive flounder but also for other cultured fish species. The development of effective vaccines and vaccination programs for fish is a continuous requirement for a sustainable aquaculture industry.

The Necessity of Vaccine Education for Pharmacists and Development of a Vaccine Leaflet for Patient Counseling (약사의 백신에 대한 교육의 필요성 및 환자 상담을 위한 소책자 개발)

  • Kim, Mi-Kyung;Kim, Hyun-Ah;Cho, Eun;Lee, Ok-Sang;Lim, Sung-Cil
    • Korean Journal of Clinical Pharmacy
    • /
    • v.21 no.3
    • /
    • pp.280-291
    • /
    • 2011
  • Vaccines are products for immunization which can provoke antibodies by eliciting immune reponses without causing disease and have played an important role in preventing fatal and contagious diseases as well as H1N1 influenza. They are classified by two following categories; lived attenuated vaccine and killed vaccine and currently commonly using vaccines are BCG, diphtheria, tetanus, mumps, measles, rubella, polio, Haemophilus influenza type b, hepatitis B, influenza etc. All vaccines must be used correctly to reach optimal therapeutic goals and also informed well to patients to decrease potential problems. In order to do, pharmacists must have good knowledge of vaccines. The purpose of this study is to evaluate the necessity of vaccine education for pharmacists and develop a vaccine leaflet for patient counseling. We have performed a survey with questionnaire for a total of 176 pharmacists and nurses(hospital pharmacists, n=65; community pharmacists, n=50; hospital nurses, n=61) from January 27th to March 12th, 2010. The questionnaire includes items about vaccine education and counseling and 12 quizzes to evaluate responders' knowledge of vaccines. We used the SPSS(Version 12. for windows) program to analyze the data. In results, 94.9% of all responders said they had not been educated on vaccines. And only 1.1% of all responders said they know about vaccines enough to counsel patients. Pharmacists who have an experience recommending vaccines to other people are 21.7%. On the other hand, nurses who have an experience recommending vaccines to other people are 55.7%(p=0.000). The mean number of correct answers at the 12 quizzes are followings; hospital pharmacist, 8.1; community pharmacist, 6.1, hospital nurses, 6.2(p=0.000). A vaccine leaflet for patient counseling is developed with several references. In conclusion, due to no opportunity of vaccine education, pharmacists have no confidence to counsel patients and lack of knowledge of vaccine. But importance of vaccine's role is increasing, pharmacists should counsel patients in vaccination. So they need vaccine education and a vaccine leaflet will be helpful for their counseling.

Serological responses and protection levels in chickens administered with Newcastle disease vaccines

  • Geumji Seung;Jiye Kim;Hyobi Kim;Ji-Yeon Kim;Yang-Ho Jang;Yeon-Hee Kim;Moon Her;Seong-Joon Yi;Keun-Woo Lee;Il Jang;Young Ju Lee
    • Korean Journal of Veterinary Research
    • /
    • v.62 no.4
    • /
    • pp.29.1-29.7
    • /
    • 2022
  • Vaccination against Newcastle disease (ND) is the most effective means of controlling the disease, and these vaccines are commercialized only after their safety and effectiveness have been verified through tests that comply with Korean Standards of National Lot Release for Veterinary Biologics. This study investigated whether a relatively convenient and safe serological test can be used in place of the challenge test using highly virulent ND virus. Hemagglutination inhibition (HI) assay and enzyme-linked immunosorbent assay (ELISA) were considered positive of log2 2 or more and cutoff value of 200 or more, respectively, in both live and inactivated vaccines. However, when the antibody levels of the live and inactivated vaccines induced using the Ulster 2C, KBNP-C4152R2L, and K148/08 strains were compared, the antibody titers for inactivated vaccines were significantly higher than those for live vaccines in both the HI assay and ELISA. A strong positive correlation was observed between HI and ELISA antibody titers. The live vaccines corresponded to a survival rates of ≥ 80% and the inactivated vaccines corresponded to 100% survival rates. This study confirmed that standard efficacy tests can serve as serological tests, and can replace the challenge test and that the vaccine approval process can be improved.

Comparison of COVID-19 Vaccines Introduced in Korea

  • Lee, Chang-Gun;Lee, Dongsup
    • Biomedical Science Letters
    • /
    • v.28 no.2
    • /
    • pp.67-82
    • /
    • 2022
  • The prevalence of SARS-CoV-2 led to inconsistent public health policies that resulted in COVID-19 containment failure. These factors resulted in increased hospitalization and death. To prevent viral spread and achieve herd immunity, the only safe and effective measure is to provide to vaccinates. Ever since the release of the SARS-CoV-2 nucleotide sequence in January of 2020, research centers and pharmaceutical companies from many countries have developed different types of vaccines including mRNA, recombinant protein, and viral vector vaccines. Prior to initiating vaccinations, phase 3 clinical trials are necessary. However, no vaccine has yet to complete a phase 3 clinical trial. Many products obtained "emergency use authorization" from governmental agencies such as WHO, FDA etc. The Korean government authorized the use of five different vaccines. The viral vector vaccine of Oxford/AstraZeneca and the Janssen showed effectiveness of 76% and 66.9%, respectively. The mRNA vaccine of Pfizer-BioNTech and Moderna showed effectiveness of 95% and 94.1%, respectively. The protein recombinant vaccine of Novavax showed an effectiveness of 90.4%. In this review, we compared the characteristics, production platform, synthesis principles, authorization, protective effects, immune responses, clinical trials and adverse effects of five different vaccines currently used in Korea. Through this review, we conceptualize the importance of selecting the optimal vaccine to prevent the COVID-19 pandemic.

Cancer Immunotherapy: Cancer Vaccines

  • Lee, Na Kyung;Kim, Hong Sung
    • Biomedical Science Letters
    • /
    • v.23 no.3
    • /
    • pp.161-165
    • /
    • 2017
  • It has well reported that host immune system is closely related to cancer growth and eradication. Among cancer immunotherapy, cancer vaccine is focused on this review. Cancer vaccine is using host immune system against various tumor antigens to treat cancer. We discuss the classification and characteristics of the preventive vaccine, therapeutic vaccine and combination cancer immunotherapy.

Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia

  • Park, Young Shil
    • Clinical and Experimental Pediatrics
    • /
    • v.64 no.8
    • /
    • pp.400-405
    • /
    • 2021
  • The development of vaccines against severe acute respiratory syndrome coronavirus 2, which features high mortality and morbidity rates, has progressed at an unprecedented rate, and vaccines are currently in use worldwide. Thrombotic events after vaccination are accompanied by thrombocytopenia, and this issue was recently termed vaccine-induced immune thrombotic thrombocytopenia. This manuscript describes recently published guidelines and other related issues and demonstrates characteristic cases.

Statistical Consideration of Vaccine Clinical Trials (백신임상시험에 대한 통계적 고찰)

  • Nam, Ju-Sun;Kang, Seung-Ho
    • The Korean Journal of Applied Statistics
    • /
    • v.24 no.4
    • /
    • pp.633-646
    • /
    • 2011
  • Clinical vaccines studies (that include cancer prevention vaccines and therapeutic vaccines) are ongoing to improve the quality of life and lengthen the human lifespan. Recently clinical trials and research on vaccines have become more active due to the prevalence of new viruses such as the A(H1N1) virus that freighted the whole word in 2009. In this paper we will describe the statistical aspects of clinical vaccine trials and outline the current situation of domestic and international vaccine development.

Asthma has an adverse effect on the production of antibody to vaccines (천식이 예방접종 후 항체 형성에 미치는 영향)

  • Sheen, Youn Ho
    • Allergy, Asthma & Respiratory Disease
    • /
    • v.6 no.6
    • /
    • pp.279-283
    • /
    • 2018
  • Asthma is considered a chronic inflammatory airway disease. Mounting evidence reports that patients with asthma are at significantly higher risk of developing communicable diseases such as invasive pneumococcal disease, Haemophilus influenza, varicella, measles, pertussis and tetanus. While impaired innate immunity may play a role in increased risk of developing these infections, suboptimal adaptive immune responses have also been reported to play a role in asthmatic subjects with regard to increased risk of infections. This review discusses the currently underrecognized immunological effect of asthma on antibody to vaccines and recommends that clinicians be aware of less optimal antibody production in response to vaccines in subjects with asthma.